Application of Pharmacogenomics Testing in a Community-based Facility
This study was designed to examine the use of pharmacogenomics (PGx) testing in a community-based facility, the adoption of the PGx recommendations by providers, and assess challenges and opportunities for pharmacists in using PGx testing in a real-world setting. This was a retrospective study invol...
Saved in:
Published in | Hospital pharmacy (Philadelphia) Vol. 58; no. 1; pp. 98 - 105 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Los Angeles, CA
SAGE Publications
01.02.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | This study was designed to examine the use of pharmacogenomics (PGx) testing in a community-based facility, the adoption of the PGx recommendations by providers, and assess challenges and opportunities for pharmacists in using PGx testing in a real-world setting. This was a retrospective study involving chart reviews of 137 patients with mood disorders who underwent PGx testing between September 2017 and December 2017. Eighty-seven patients who met inclusion and exclusion criteria were analyzed to evaluate the impact of PGx testing on psychotropic medication treatment and to evaluate the PGx test process. PGx test results were used by providers to guide their therapeutic modifications based on the gene-drug interactions identified. Patient medication use increased from 125 to 190 (P < .001) prescriptions. Patient medication belonging to no gene-drug interaction significantly increased from 46.4% to 87.4% (P < .001), medications belonging to moderate and significant gene-drug interaction decreased from 32.8% to 7.9% (P < .001) and 11.2% to 2.1% (P = .012), respectively. 88.5% of patients’ psychotropic medication treatment after PGx testing was consistent with the PGx test report recommendations. The PGx test lengths of time analysis indicated that patient follow-up exceeded the standard time set by guidelines at multiple steps in the test process. There are multiple opportunities for pharmacists to become involved in the PGx testing process to improve patient care. |
---|---|
AbstractList | This study was designed to examine the use of pharmacogenomics (PGx) testing in a community-based facility, the adoption of the PGx recommendations by providers, and assess challenges and opportunities for pharmacists in using PGx testing in a real-world setting. This was a retrospective study involving chart reviews of 137 patients with mood disorders who underwent PGx testing between September 2017 and December 2017. Eighty-seven patients who met inclusion and exclusion criteria were analyzed to evaluate the impact of PGx testing on psychotropic medication treatment and to evaluate the PGx test process. PGx test results were used by providers to guide their therapeutic modifications based on the gene-drug interactions identified. Patient medication use increased from 125 to 190 ( P < .001) prescriptions. Patient medication belonging to no gene-drug interaction significantly increased from 46.4% to 87.4% ( P < .001), medications belonging to moderate and significant gene-drug interaction decreased from 32.8% to 7.9% ( P < .001) and 11.2% to 2.1% ( P = .012), respectively. 88.5% of patients’ psychotropic medication treatment after PGx testing was consistent with the PGx test report recommendations. The PGx test lengths of time analysis indicated that patient follow-up exceeded the standard time set by guidelines at multiple steps in the test process. There are multiple opportunities for pharmacists to become involved in the PGx testing process to improve patient care. This study was designed to examine the use of pharmacogenomics (PGx) testing in a community-based facility, the adoption of the PGx recommendations by providers, and assess challenges and opportunities for pharmacists in using PGx testing in a real-world setting. This was a retrospective study involving chart reviews of 137 patients with mood disorders who underwent PGx testing between September 2017 and December 2017. Eighty-seven patients who met inclusion and exclusion criteria were analyzed to evaluate the impact of PGx testing on psychotropic medication treatment and to evaluate the PGx test process. PGx test results were used by providers to guide their therapeutic modifications based on the gene-drug interactions identified. Patient medication use increased from 125 to 190 ( < .001) prescriptions. Patient medication belonging to no gene-drug interaction significantly increased from 46.4% to 87.4% ( < .001), medications belonging to moderate and significant gene-drug interaction decreased from 32.8% to 7.9% ( < .001) and 11.2% to 2.1% ( = .012), respectively. 88.5% of patients' psychotropic medication treatment after PGx testing was consistent with the PGx test report recommendations. The PGx test lengths of time analysis indicated that patient follow-up exceeded the standard time set by guidelines at multiple steps in the test process. There are multiple opportunities for pharmacists to become involved in the PGx testing process to improve patient care. This study was designed to examine the use of pharmacogenomics (PGx) testing in a community-based facility, the adoption of the PGx recommendations by providers, and assess challenges and opportunities for pharmacists in using PGx testing in a real-world setting. This was a retrospective study involving chart reviews of 137 patients with mood disorders who underwent PGx testing between September 2017 and December 2017. Eighty-seven patients who met inclusion and exclusion criteria were analyzed to evaluate the impact of PGx testing on psychotropic medication treatment and to evaluate the PGx test process. PGx test results were used by providers to guide their therapeutic modifications based on the gene-drug interactions identified. Patient medication use increased from 125 to 190 ( P < .001) prescriptions. Patient medication belonging to no gene-drug interaction significantly increased from 46.4% to 87.4% ( P < .001), medications belonging to moderate and significant gene-drug interaction decreased from 32.8% to 7.9% ( P < .001) and 11.2% to 2.1% ( P = .012), respectively. 88.5% of patients’ psychotropic medication treatment after PGx testing was consistent with the PGx test report recommendations. The PGx test lengths of time analysis indicated that patient follow-up exceeded the standard time set by guidelines at multiple steps in the test process. There are multiple opportunities for pharmacists to become involved in the PGx testing process to improve patient care. This study was designed to examine the use of pharmacogenomics (PGx) testing in a community-based facility, the adoption of the PGx recommendations by providers, and assess challenges and opportunities for pharmacists in using PGx testing in a real-world setting. This was a retrospective study involving chart reviews of 137 patients with mood disorders who underwent PGx testing between September 2017 and December 2017. Eighty-seven patients who met inclusion and exclusion criteria were analyzed to evaluate the impact of PGx testing on psychotropic medication treatment and to evaluate the PGx test process. PGx test results were used by providers to guide their therapeutic modifications based on the gene-drug interactions identified. Patient medication use increased from 125 to 190 (P < .001) prescriptions. Patient medication belonging to no gene-drug interaction significantly increased from 46.4% to 87.4% (P < .001), medications belonging to moderate and significant gene-drug interaction decreased from 32.8% to 7.9% (P < .001) and 11.2% to 2.1% (P = .012), respectively. 88.5% of patients' psychotropic medication treatment after PGx testing was consistent with the PGx test report recommendations. The PGx test lengths of time analysis indicated that patient follow-up exceeded the standard time set by guidelines at multiple steps in the test process. There are multiple opportunities for pharmacists to become involved in the PGx testing process to improve patient care.This study was designed to examine the use of pharmacogenomics (PGx) testing in a community-based facility, the adoption of the PGx recommendations by providers, and assess challenges and opportunities for pharmacists in using PGx testing in a real-world setting. This was a retrospective study involving chart reviews of 137 patients with mood disorders who underwent PGx testing between September 2017 and December 2017. Eighty-seven patients who met inclusion and exclusion criteria were analyzed to evaluate the impact of PGx testing on psychotropic medication treatment and to evaluate the PGx test process. PGx test results were used by providers to guide their therapeutic modifications based on the gene-drug interactions identified. Patient medication use increased from 125 to 190 (P < .001) prescriptions. Patient medication belonging to no gene-drug interaction significantly increased from 46.4% to 87.4% (P < .001), medications belonging to moderate and significant gene-drug interaction decreased from 32.8% to 7.9% (P < .001) and 11.2% to 2.1% (P = .012), respectively. 88.5% of patients' psychotropic medication treatment after PGx testing was consistent with the PGx test report recommendations. The PGx test lengths of time analysis indicated that patient follow-up exceeded the standard time set by guidelines at multiple steps in the test process. There are multiple opportunities for pharmacists to become involved in the PGx testing process to improve patient care. |
Author | Arbet, Renee Noel Lin, Alex C. Paul, Sue Wang, Jingyi |
AuthorAffiliation | 2 SyneRxgy Consulting, LLC., Cincinnati, OH, USA 3 Main Line Health – Riddle Hospital, Media, PA, USA 1 University of Cincinnati, Cincinnati, OH, USA |
AuthorAffiliation_xml | – name: 2 SyneRxgy Consulting, LLC., Cincinnati, OH, USA – name: 1 University of Cincinnati, Cincinnati, OH, USA – name: 3 Main Line Health – Riddle Hospital, Media, PA, USA |
Author_xml | – sequence: 1 givenname: Jingyi orcidid: 0000-0001-8958-6041 surname: Wang fullname: Wang, Jingyi – sequence: 2 givenname: Sue surname: Paul fullname: Paul, Sue – sequence: 3 givenname: Renee Noel surname: Arbet fullname: Arbet, Renee Noel – sequence: 4 givenname: Alex C. surname: Lin fullname: Lin, Alex C. email: lina@ucmail.uc.edu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36644742$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE9LAzEQxYMoWqsfwIvs0cvWZGeT7F4EKfUPCHqo55BNp9uU3aRudgW_vSmtogiehmF-8-bNOyWHzjsk5ILRCWNSXlPKCi4LmWWMQS5KOCAjVuY8ZRmHQzLaztMtcEJOQ1jHVkIGx-QEhMhzmWcjMrvdbBprdG-9S_wyeVnprtXG1-h8a01I5hh66-rEukQnU9-2g7P9R1rpgIvkThvbxPaMHC11E_B8X8fk9W42nz6kT8_3j9Pbp9RALvu0ZCAN1WWFlAJoXi2gYoJpkUm-XGCJSAvBJTelxIpVEkAYNCwTyKNjnsOY3Ox0N0PV4sKg6zvdqE1nW919KK-t-j1xdqVq_67KAuLrNApc7QU6_zbE11Rrg8Gm0Q79EFQmhaBCcoCIsh1qOh9Ch8vvM4yqbfzqT_xx5_Knv--Nr7wjMNkBQdeo1n7oXMzrH8VPHJCPLQ |
Cites_doi | 10.1016/j.bbi.2020.11.023 10.1016/j.jad.2020.09.065 10.2217/17410541.2.4.325 10.1016/j.cll.2008.05.003 10.1177/1357633X18822575 10.1016/j.lana.2021.100091 10.1002/cpt.597 10.1097/FPC.0b013e3283649b9a 10.1016/j.jad.2020.08.001 10.1002/cpt.147 10.1016/j.jpsychires.2019.01.003 10.18553/jmcp.2018.24.8.726 10.1007/s13167-017-0112-8 10.1017/S109285291600095X 10.1007/s11920-007-0061-3 10.1258/cvd.2012.012001 10.9740/mhc.2016.01.054 10.2147/PPA.S138750 10.1176/appi.ps.201300059 |
ContentType | Journal Article |
Copyright | The Author(s) 2022 The Author(s) 2022. The Author(s) 2022 2022 SAGE Publications |
Copyright_xml | – notice: The Author(s) 2022 – notice: The Author(s) 2022. – notice: The Author(s) 2022 2022 SAGE Publications |
DBID | NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1177/00185787221134693 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1945-1253 |
EndPage | 105 |
ExternalDocumentID | 10_1177_00185787221134693 36644742 10.1177_00185787221134693 |
Genre | Journal Article |
GroupedDBID | --- -TM 04C 0R~ 1CY 4.4 53G 54M 5GY 5RE 8F7 AABMB AACMV AADUE AAEWN AAKAS AARIX AATAA AAVQN AAWTL ABCCA ABFWQ ABJIS ABJNI ABKRH ABLUO ABPNF ABQXT ABRHV ACARO ACDSZ ACDXX ACFEJ ACGFS ACOFE ACOXC ACROE ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADRRZ ADZCM AEPTA AEQLS AESZF AEWDL AEWHI AEXNY AFEET AFKRG AFMOU AFQAA AFUIA AGKLV AGNHF AIIQI AIOMO AJUZI AJXAJ ALMA_UNASSIGNED_HOLDINGS AMCVQ ANDLU ARTOV BAWUL BBRGL BDDNI BKIIM BPACV C1A CFDXU DC- DC. DF. DIK DOPDO DV7 EBS EIHBH EJD F5P FHBDP GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION GX1 HYE HZ~ J8X JCYGO K.F LSO M4V MEI MET MTL O9- OK1 OVD RPM SAFTQ SCNPE SFC SHG SPV TEORI WH7 YCJ YFH ZGI ZONMY ZPPRI ZRKOI ZY1 ACJER ALKWR H13 NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c347t-9137c0a9be0033a5bd3b161a6275fde9ee086575c97eb1b7336cec126e5366543 |
IEDL.DBID | RPM |
ISSN | 0018-5787 |
IngestDate | Tue Sep 17 21:30:36 EDT 2024 Tue Sep 10 16:30:59 EDT 2024 Wed Oct 09 16:45:45 EDT 2024 Wed Oct 09 10:19:28 EDT 2024 Tue Jul 16 20:34:19 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | psychiatric clinical pathways gene therapy |
Language | English |
License | The Author(s) 2022. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c347t-9137c0a9be0033a5bd3b161a6275fde9ee086575c97eb1b7336cec126e5366543 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-8958-6041 |
PMID | 36644742 |
PQID | 2766067533 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9837320 proquest_miscellaneous_2766067533 crossref_primary_10_1177_00185787221134693 pubmed_primary_36644742 sage_journals_10_1177_00185787221134693 |
PublicationCentury | 2000 |
PublicationDate | 2023-02-01 |
PublicationDateYYYYMMDD | 2023-02-01 |
PublicationDate_xml | – month: 02 year: 2023 text: 2023-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Los Angeles, CA |
PublicationPlace_xml | – name: Los Angeles, CA – name: United States – name: Sage CA: Los Angeles, CA |
PublicationTitle | Hospital pharmacy (Philadelphia) |
PublicationTitleAlternate | Hosp Pharm |
PublicationYear | 2023 |
Publisher | SAGE Publications |
Publisher_xml | – name: SAGE Publications |
References | Pappa, Ntella, Giannakas, Giannakoulis, Papoutsi, Katsaounou 2020; 92 Kim, Magness, Nelson, Baron, Brixner 2018; 24 Xie, Frueh 2005; 2 Mrazek, Hornberger, Altar, Degtiar 2014; 65 Hall-Flavin, Winner, Allen 2013; 23 Xiong, Lipsitz, Nasri 2020; 277 de Leon, Arranz, Ruaño 2008; 28 Cunningham 2009; 28 2010 Stahl 2017; 22 Warden, Rush, Trivedi, Fava, Wisniewski 2007; 9 Armstrong 2011; 283 Belle, Singh 2008; 77 Ross, Anand, Joseph, Paré 2012; 1 Ware, Tillery, Linder 2016; 6 Amare, Schubert, Baune 2017; 8 Ettman, Cohen, Abdalla 2022; 5 Cohen, Taveira, Wu, Pirraglia 2020; 26 Hicks, Bishop, Sangkuhl 2015; 98 Greden, Parikh, Rothschild 2019; 111 Hicks, Sangkuhl, Swen 2017; 102 Novick, Montgomery, Vorstenbosch, Moneta, Dueñas, Haro 2017; 11 Daly, Sutin, Robinson 2021; 278 Groessl, Tally, Hillery, Maciel, Garces 2018; 24 Belle DJ (bibr29-00185787221134693) 2008; 77 bibr8-00185787221134693 bibr5-00185787221134693 Armstrong C. (bibr26-00185787221134693) 2011; 283 bibr2-00185787221134693 Kim K (bibr27-00185787221134693) 2018; 24 bibr9-00185787221134693 bibr19-00185787221134693 bibr16-00185787221134693 bibr3-00185787221134693 bibr30-00185787221134693 bibr23-00185787221134693 bibr10-00185787221134693 bibr13-00185787221134693 bibr20-00185787221134693 bibr17-00185787221134693 bibr1-00185787221134693 bibr4-00185787221134693 bibr11-00185787221134693 bibr7-00185787221134693 bibr24-00185787221134693 bibr21-00185787221134693 bibr14-00185787221134693 bibr12-00185787221134693 Cunningham PJ. (bibr6-00185787221134693) 2009; 28 bibr22-00185787221134693 bibr28-00185787221134693 bibr15-00185787221134693 bibr18-00185787221134693 National Collaborating Centre for Mental Health UK (bibr25-00185787221134693) 2010 |
References_xml | – volume: 277 start-page: 55 issue: 1 year: 2020 end-page: 64 article-title: Impact of COVID-19 pandemic on mental health in the general population: a systematic review publication-title: J Affect Disord contributor: fullname: Nasri – volume: 5 start-page: 100091 year: 2022 article-title: Persistent depressive symptoms during COVID-19: a national, population-representative, longitudinal study of U.S. adults publication-title: Lancet Reg Health Am contributor: fullname: Abdalla – volume: 24 start-page: 1250 issue: 12 year: 2018 end-page: 1259 article-title: Clinical utility of pharmacogenetic testing and a clinical decision support tool to enhance the identification of drug therapy problems through medication therapy management in polypharmacy patients publication-title: J Manag Care Spec Pharm contributor: fullname: Brixner – volume: 24 start-page: 726 issue: 8 year: 2018 end-page: 734 article-title: Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder publication-title: J Manag Care Spec Pharm contributor: fullname: Garces – volume: 28 start-page: 599 issue: 4 year: 2008 end-page: 617 article-title: Pharmacogenetic testing in psychiatry: a review of features and clinical realities publication-title: Clin Lab Med contributor: fullname: Ruaño – year: 2010 publication-title: Depression in adults with a chronic society – volume: 77 year: 2008 article-title: Genetic factors in drug metabolism publication-title: Am Fam Physician contributor: fullname: Singh – volume: 2 start-page: 325 issue: 4 year: 2005 end-page: 337 article-title: Pharmacogenomics steps toward personalized medicine publication-title: Per Med contributor: fullname: Frueh – volume: 111 start-page: 59 year: 2019 end-page: 67 article-title: Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study publication-title: J Psychiatr Res contributor: fullname: Rothschild – volume: 278 start-page: 131 year: 2021 end-page: 135 article-title: Depression reported by US adults in 2017–2018 and March and April 2020 publication-title: J Affect Disord contributor: fullname: Robinson – volume: 11 start-page: 1859 year: 2017 end-page: 1868 article-title: Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study publication-title: Patient Prefer Adherence contributor: fullname: Haro – volume: 26 start-page: 294 issue: 5 year: 2020 end-page: 302 article-title: Pharmacist-led telehealth disease management program for patients with diabetes and depression publication-title: J Telemed Telecare contributor: fullname: Pirraglia – volume: 1 start-page: 1 issue: 1 year: 2012 end-page: 13 article-title: Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues publication-title: JRSM Cardiovasc Dis contributor: fullname: Paré – volume: 28 issue: 3 year: 2009 article-title: Beyond parity: Primary Care Physicians' Perspectives on access to mental health care publication-title: Health Aff contributor: fullname: Cunningham – volume: 92 start-page: 245 year: 2020 end-page: 907 article-title: Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: a systematic review and meta-analysis publication-title: Brain Behav Immun contributor: fullname: Katsaounou – volume: 65 start-page: 977 issue: 8 year: 2014 end-page: 987 article-title: A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013 publication-title: Psychiatr Serv contributor: fullname: Degtiar – volume: 6 start-page: 54 issue: 1 year: 2016 end-page: 61 article-title: General pharmacokinetic/pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder publication-title: Ment Health Clin contributor: fullname: Linder – volume: 102 start-page: 37 issue: 1 year: 2017 end-page: 44 article-title: Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update publication-title: Clin Pharmacol Ther contributor: fullname: Swen – volume: 22 start-page: 1 issue: 1 year: 2017 end-page: 4 article-title: Psychiatric pharmacogenomics: how to integrate into clinical practice publication-title: CNS Spectr contributor: fullname: Stahl – volume: 8 start-page: 211 issue: 3 year: 2017 end-page: 227 article-title: Pharmacogenomics in the treatment of mood disorders: strategies and opportunities for personalized psychiatry publication-title: EPMA J contributor: fullname: Baune – article-title: How can I use the clinical considerations to help interpret the GeneSight report? – volume: 23 start-page: 535 issue: 10 year: 2013 end-page: 548 article-title: Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting publication-title: Pharmacogenet Genomics contributor: fullname: Allen – volume: 283 start-page: 1219 issue: 10 year: 2011 article-title: APA releases guidelines on treatment of patients with major depressive disorder publication-title: Am Fam Phys contributor: fullname: Armstrong – volume: 9 start-page: 449 issue: 6 year: 2007 end-page: 459 article-title: The STAR*D Project results: a comprehensive review of findings publication-title: Curr Psychiatry Rep contributor: fullname: Wisniewski – volume: 98 start-page: 127 issue: 2 year: 2015 end-page: 134 article-title: Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors publication-title: Clin Pharmacol Ther contributor: fullname: Sangkuhl – ident: bibr1-00185787221134693 – ident: bibr12-00185787221134693 doi: 10.1016/j.bbi.2020.11.023 – volume: 28 issue: 3 year: 2009 ident: bibr6-00185787221134693 publication-title: Health Aff contributor: fullname: Cunningham PJ. – ident: bibr11-00185787221134693 doi: 10.1016/j.jad.2020.09.065 – volume: 24 start-page: 1250 issue: 12 year: 2018 ident: bibr27-00185787221134693 publication-title: J Manag Care Spec Pharm contributor: fullname: Kim K – ident: bibr3-00185787221134693 doi: 10.2217/17410541.2.4.325 – ident: bibr24-00185787221134693 – volume: 77 year: 2008 ident: bibr29-00185787221134693 publication-title: Am Fam Physician contributor: fullname: Belle DJ – ident: bibr4-00185787221134693 doi: 10.1016/j.cll.2008.05.003 – ident: bibr28-00185787221134693 doi: 10.1177/1357633X18822575 – ident: bibr10-00185787221134693 doi: 10.1016/j.lana.2021.100091 – ident: bibr17-00185787221134693 doi: 10.1002/cpt.597 – year: 2010 ident: bibr25-00185787221134693 publication-title: Depression in adults with a chronic society contributor: fullname: National Collaborating Centre for Mental Health UK – ident: bibr21-00185787221134693 doi: 10.1097/FPC.0b013e3283649b9a – ident: bibr13-00185787221134693 doi: 10.1016/j.jad.2020.08.001 – ident: bibr16-00185787221134693 doi: 10.1002/cpt.147 – ident: bibr20-00185787221134693 doi: 10.1016/j.jpsychires.2019.01.003 – ident: bibr5-00185787221134693 – ident: bibr22-00185787221134693 doi: 10.18553/jmcp.2018.24.8.726 – ident: bibr15-00185787221134693 doi: 10.1007/s13167-017-0112-8 – ident: bibr19-00185787221134693 doi: 10.1017/S109285291600095X – ident: bibr18-00185787221134693 – ident: bibr30-00185787221134693 – ident: bibr8-00185787221134693 doi: 10.1007/s11920-007-0061-3 – ident: bibr23-00185787221134693 – ident: bibr2-00185787221134693 doi: 10.1258/cvd.2012.012001 – ident: bibr14-00185787221134693 doi: 10.9740/mhc.2016.01.054 – ident: bibr7-00185787221134693 doi: 10.2147/PPA.S138750 – volume: 283 start-page: 1219 issue: 10 year: 2011 ident: bibr26-00185787221134693 publication-title: Am Fam Phys contributor: fullname: Armstrong C. – ident: bibr9-00185787221134693 doi: 10.1176/appi.ps.201300059 |
SSID | ssj0017323 |
Score | 2.3085563 |
Snippet | This study was designed to examine the use of pharmacogenomics (PGx) testing in a community-based facility, the adoption of the PGx recommendations by... |
SourceID | pubmedcentral proquest crossref pubmed sage |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 98 |
SubjectTerms | Original |
Title | Application of Pharmacogenomics Testing in a Community-based Facility |
URI | https://journals.sagepub.com/doi/full/10.1177/00185787221134693 https://www.ncbi.nlm.nih.gov/pubmed/36644742 https://www.proquest.com/docview/2766067533/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC9837320 |
Volume | 58 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEB5aT4KIb-ujRBAFcW13J5vsHkWsIig9VOhtSbKpFuxWbD3035vZR2sVL54TsiEzu5lv55tvAE5DwVXMY-HZQYQej4z0dBoYh3l4jFpgqvKuJY9P4v6ZP_TDfg3CqhYmJ-0bPbzK3kZX2fA151a-j0yr4om1uo83sUNVGLRbdahLxAqil6kDN1Kklf3II3csU5m5ylKblI8iGTjUgw4XUhMdFC4ikDxYvpd-BZu_OZPfiF_5XdTZgPUyiGTXxWY3oWazLTjrFirUs0vWWxRVTS7ZGesu9KlnW7BW_KpjRQXSNtxeL5LYbDyYzyb51pFbgfVIiSN7YcOMKVZWlExnHl2AKesoQ_Ta2Q48d257N_de2V3BM8jllFLu0rRVrC31c1OhTlG78E-RbPEgtbG1Du24YM7E0n3PNckmGmv8QNgQqWUx7sJKNs7sPjCqBghtEKkYBU9RRDw0bY0DoX2ephg14KI62-S9ENFI_Epn_KdNGnBSnX7iXJ3yFyqz489JEkghCOCgm7NXWGO-XGXGBsglO80nkIz28ojzrlxOu_SmBpyTRZPyHZ78vcODfz_jEFapXX3B-j6ClenHpz12Qc1UN6F-1_ebuSt_Afvx8TU |
link.rule.ids | 230,315,733,786,790,891,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-N8QDSxMdgo3waCQ0JLf2wHTt5nKZVBdapDx3aW2Q7LlTQdKLpQ_nruYuTlm7iAZ5tObHuLneX-93vAN7FSppUpiryk0REMnE6sjl3mPPIVFglclNNLRleqMGl_HQVX-1A3PTCVKB9Z6ft4sesXUy_VdjK65nrNDixzmh4mmJWJXi3cwfuor1y3STpdfEA10JhuZdEpJB1MbPiWeoS91GiOeY9AjNDGqMjFMYEWvJtz3Qr3LyNmvwD-lV5o_5D-NLcI4BQvreXpW27XzcoHv_5oo_gQR2fspOw_Bh2fLEPR6NAcL06ZuNNv9bimB2x0Yb6erUPe-EvIAvNTU_g7GRTH2fzyXo3McPO8AQ2JpKP4iubFsywulmlXEXkW3PWN46Qu6uncNk_G58OonpwQ-SE1CVV87XrmtR6GhVnYpsLi5GlIUbkSe5T7zGRwjjRpRpdhSVGRuddjysfC5qGLA5gt5gX_hkwajSIPU9MKpTMhUpk7LpWTJTtyTwXSQs-NELLrgM_R9ZrKMxvCrsFbxuxZmhFVBoxhZ8vFxnXSlHuJHDPYRDz-rhGP1qgtxRgvYEYurdXUJ4VU3ctvxa8J1XJ6s_D4u9v-Py_n_EG7g3Gw_Ps_OPF5xdwn2MsFsDlL2G3_Ln0rzB2Ku3rylJ-A85YEks |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9tAEB5RKlWVqj5oadPnVqqoVOE8dtdr7xEBEX2AcggS6sXalyGCOFHjHMKvZ8drJwTUC-cdrb2aWc-M55tvAL7FgivJpYhcnrKIpyaJtKXG5zxcMi2YVdXUkuMTcXTKf53FZ7dGfVWgfaNH7eJq3C5GFxW2cjo2nQYn1hkc70ufVTHa7Uxt3nkEj_2dpbJJ1OsCgl8PxeVeGqFR1gXNimupi_xHaUJ97sN8doijdJjwcUHC6bp3uhdy3kdO3oJ_VR6p_wL-NmcJQJTL9rzUbXN9h-bxQYd9Cc_rOJXsBZFXsOGKLdgZBKLrxS4Zrvq2ZrtkhwxWFNiLLXgW_gaS0OT0Gg73VnVyMsmX0sgQO_Y7kCGSfRTnZFQQReqmlXIRoY-1pK8MIngXb-C0fzjcP4rqAQ6RYTwpsaqfmK6S2uHIOBVry7SPMBUyI-fWSed8QuXjRSMT7zI0MjMaZ3pUuJjhVGS2DZvFpHDvgGDDQexoqiQT3DKR8th0NcuF7nFrWdqCH43ismng6ch6DZX5XYW34Guj2szfJiyRqMJN5rOMJkJgDsW8zNug6uV2jY20IFkzgqUAMnWvr3idVozdtQ5b8B3NJas_E7P_v-H7Bz_jCzwZHPSzPz9Pfn-Ap9SHZAFj_hE2y39z98mHUKX-XF2WG5W8FMs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Application+of+Pharmacogenomics+Testing+in+a+Community-based+Facility&rft.jtitle=Hospital+pharmacy+%28Philadelphia%29&rft.au=Wang%2C+Jingyi&rft.au=Paul%2C+Sue&rft.au=Arbet%2C+Renee+Noel&rft.au=Lin%2C+Alex+C&rft.date=2023-02-01&rft.issn=0018-5787&rft.volume=58&rft.issue=1&rft.spage=98&rft_id=info:doi/10.1177%2F00185787221134693&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0018-5787&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0018-5787&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0018-5787&client=summon |